LY3437943 bioavailability and safety evaluated across injection sites in healthy participants with high BMI

For subcutaneously administered drugs, the injection site can significantly influence drug absorption, affecting overall bioavailability and patient experience. This is particularly relevant for long-acting peptides targeting metabolic conditions, where consistent drug exposure is crucial for efficacy and patient adherence. Understanding these pharmacokinetic differences is vital for optimizing dosing protocols and patient education. LY3437943 is a novel multi-agonist peptide, and its optimal delivery method, including preferred injection sites, needs thorough investigation to ensure consistent exposure and maximize therapeutic benefit in populations with conditions like obesity or high BMI.

This Phase 1 clinical trial, NCT05959096, was conducted in two parts (A and B) with healthy participants exhibiting a high body mass index. Part A investigated the relative bioavailability of a single subcutaneous (SC) dose of LY3437943 when administered to the upper arm and thigh, compared to the abdomen. Part B involved intravenous (IV) administration of LY3437943 to evaluate its safety and tolerability, alongside collecting information on any experienced side effects. The study aimed to characterize the amount of LY3437943 entering the bloodstream and its elimination rate. Each participant's total study duration was approximately up to 157 days for Part A and 99 days for Part B.

The abstract for this completed Phase 1 clinical trial does not present specific pharmacokinetic or safety results. It outlines the study's objectives to evaluate the relative bioavailability of LY3437943 when administered subcutaneously at different injection sites (upper arm, thigh, abdomen) and to assess its safety and tolerability following intravenous administration. Detailed data regarding absorption, distribution, metabolism, excretion (ADME) profiles, or adverse event rates are not included in this summary. The study aimed to provide critical data on how injection site influences drug exposure and to characterize the safety profile of LY3437943 through both SC and IV routes, but these findings are pending publication.